Sleep medication helped cannabis users sleep during early withdrawal but did not significantly boost quit rates

In a 12-week trial of 127 adults seeking cannabis cessation, zolpidem prevented early withdrawal sleep disturbance but did not significantly increase abstinence rates (27% vs 15% on placebo), with high dropout in both groups.

Lee, Dustin C et al.·Journal of substance use and addiction treatment·2024·Moderate Evidencerandomized controlled trial
RTHC-05462Randomized controlled trialModerate Evidence2024RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
randomized controlled trial
Evidence
Moderate Evidence
Sample
N=127

What This Study Found

Placebo participants but not zolpidem-XR participants showed significant sleep disturbance during week 1 of cannabis cessation. Abstinence rates were numerically higher with zolpidem-XR (27% vs 15%) but not statistically significant. Sleep disturbance emerged in the medication group after treatment stopped. Treatment retention was poor (about 50% dropout in both groups).

Key Numbers

127 participants; 27% abstinent on zolpidem-XR vs 15% on placebo (not significant); ~50% dropout in both groups; sleep disturbance prevented during medication but emerged after stopping; objective polysomnography used

How They Did This

Twelve-week randomized, double-blind, placebo-controlled trial of 127 adults with cannabis use disorder. All received computerized behavioral therapy and abstinence-based contingency management. Zolpidem-XR or placebo was provided during treatment. In-home ambulatory polysomnography measured sleep objectively.

Why This Research Matters

Sleep disturbance is one of the most common reasons people relapse when trying to quit cannabis. This trial provides important evidence that pharmacological sleep support can help during early withdrawal.

The Bigger Picture

The rebound sleep disturbance after stopping zolpidem suggests that simply delaying withdrawal symptoms is insufficient. Longer or different approaches to managing cannabis withdrawal sleep problems may be needed.

What This Study Doesn't Tell Us

Not powered to detect significant differences in abstinence; high dropout rate reduces interpretability; medication adherence was challenging; sleep medication stopped at end of treatment causing rebound; unclear optimal treatment duration

Questions This Raises

  • ?Would a longer course of sleep medication improve cannabis cessation?
  • ?Would non-pharmacological sleep interventions (CBT-I) provide more durable benefits?
  • ?Is sleep disturbance a mediator or just a correlate of cannabis relapse?

Trust & Context

Key Stat:
27% vs 15% abstinence (not significant); 50% dropout
Evidence Grade:
Well-designed RCT with objective sleep measurement, but underpowered for the primary outcome and hampered by high attrition.
Study Age:
2024 study
Original Title:
Randomized controlled trial of zolpidem as a pharmacotherapy for cannabis use disorder.
Published In:
Journal of substance use and addiction treatment, 156, 209180 (2024)
Database ID:
RTHC-05462

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

Did sleep medication help people quit cannabis?

It helped with sleep but not significantly with quitting. Zolpidem-XR prevented the sleep problems that typically occur in the first week of cannabis cessation, and numerically more participants quit (27% vs 15%), but the difference was not statistically significant.

What happened when the medication stopped?

Sleep disturbance that was prevented during medication treatment emerged after zolpidem-XR was discontinued, suggesting the medication delayed rather than resolved withdrawal-related sleep problems. About half of participants in both groups dropped out before completing the trial.

Read More on RethinkTHC

Cite This Study

RTHC-05462·https://rethinkthc.com/research/RTHC-05462

APA

Lee, Dustin C; Schlienz, Nicolas J; Herrmann, Evan S; Martin, Erin L; Leoutsakos, Jeannie; Budney, Alan J; Smith, Michael T; Tompkins, D Andrew; Hampson, Aidan J; Vandrey, Ryan. (2024). Randomized controlled trial of zolpidem as a pharmacotherapy for cannabis use disorder.. Journal of substance use and addiction treatment, 156, 209180. https://doi.org/10.1016/j.josat.2023.209180

MLA

Lee, Dustin C, et al. "Randomized controlled trial of zolpidem as a pharmacotherapy for cannabis use disorder.." Journal of substance use and addiction treatment, 2024. https://doi.org/10.1016/j.josat.2023.209180

RethinkTHC

RethinkTHC Research Database. "Randomized controlled trial of zolpidem as a pharmacotherapy..." RTHC-05462. Retrieved from https://rethinkthc.com/research/lee-2024-randomized-controlled-trial-of

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.